Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

MGNX Relative to the S&P 500

MGNX Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the MacroGenics Inc. (NASD:MGNX) seasonal charts above shows that a Buy Date of November 22 and a Sell Date of February 26 has resulted in a geometric average return of 0.05% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 33.21% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

To download MGNX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: MGNX